Vicore Pharma Holding AB
VCREHealthcare|Biotechnology|Sweden
$14.01
-0.22 (-1.57%)
Tangible Book
$3.86
About
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
Stock Price
-13.8%(1Y)
Pipeline Summary
11 total trials4
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
Completed: 10Active: 1
Active Trials (1)
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686Idiopathic Pulmonary Fibrosis (IPF)
Phase 2Active
Enrollment: 378 participants
BioScore
5.3/10
Watchlist
Ownership
Data last updated: Jul 13, 2026, 12:41 PM